No Side Effects at All — Is the Treatment Working?

Yes. Many patients on checkpoint-inhibitor immunotherapy have mild side effects or none at all, and this is completely normal — not a sign the treatment is failing. How strongly each person's immune system reacts once checkpoint inhibitors release its natural brakes varies widely between patients, regardless of how well the treatment is working against the cancer.

This is one of the most common worries we hear from patients on active treatment, and it deserves a straight answer: feeling normal is not a problem to solve. It is, in fact, the experience of a large share of patients who go on to respond well.

No. There is no reliable evidence that having zero side effects predicts a weaker response to immunotherapy. Response and side effects come from different parts of how checkpoint inhibitors act on your immune system, so one does not need to happen for the other to succeed.

It's a natural, counter-intuitive worry — most treatments people are familiar with signal "it's working" through some felt effect, so no effect at all can feel like nothing is happening. But NCCN and ASCO guidance on immune checkpoint inhibitors treats irAEs and anti-tumour response as two separate things, tracked on two separate timelines, precisely because one does not reliably predict the other.

Immune-related side effects, when they occur, tend to follow rough timing windows depending on which system is affected — but for every one of them, a share of patients simply never notice anything at all, at any point in treatment. The table below lines up typical onset against how common it is to skip that effect entirely.

This table is a general reference, not a personal prediction — your own oncology team is best placed to say what's typical for your specific regimen and stage of treatment.

Checkpoint inhibitors work by releasing a brake — usually PD-1, PD-L1 or CTLA-4 — that normally keeps the immune system in check. Once that brake is released, how visibly the immune system reacts against healthy tissue depends on each person's own immune biology, prior immune sensitisation, and other individual factors that vary from patient to patient. That variation happens independently of how effectively the released immune activity is acting against the tumour itself.

This is why two patients on an identical protocol can have very different experiences — one with a rash and mild fatigue, another with nothing noticeable at all — while both are being monitored on the same response-assessment schedule. Neither pattern by itself says anything about how the cancer is responding.

Because symptoms aren't a reliable guide either way, response assessment relies entirely on scheduled tests. Here's what that looks like in practice.

1. 1

   Baseline imaging before treatment starts

   A CT scan (and PET-CT where relevant, coordinated at a partner imaging centre) sets the starting picture every later scan is compared against.

2. 2

   Scheduled follow-up scans

   Imaging repeats at intervals your oncologist sets — typically every 2–3 cycles — whether you've had zero side effects or several in between.

3. 3

   Relevant tumour markers

   Where a marker is useful for your specific cancer, blood tests track it alongside imaging, not as a stand-in for it.

4. 4

   Clinical review at every visit

   Your oncologist reviews scans, markers, and how you're feeling together — no single piece decides the picture alone.

5. 5

   Your reported symptoms are still recorded

   Even "nothing to report" is logged at every visit — it helps your team build an accurate picture of your individual pattern over time, even though it isn't used to judge response.

This question has a mirror image, and a few companion pages worth reading alongside it.

• Do Side Effects Mean the Immunotherapy Is Working? — the other direction of this exact worry, answered in full.
• Fatigue on Immunotherapy: When It Is Ordinary and When It Is Not — what typical, mild fatigue looks like versus what needs a call.
• Fever During Immunotherapy: Infection or Immune Reaction? — telling an ordinary fever apart from one that needs same-day attention.
• Can You Take Your Regular Medicines During Immunotherapy? — what to check with your team before combining treatments.
• Immunotherapy at CION Cancer Clinics — how we monitor both response and side effects together, from the first infusion onward.

Your Care Team Tracks Response on Its Own Schedule

Scans, tests, and clinical review — not daily symptoms — are what our specialists use to confirm your immunotherapy is working.